4 . 2020

Antiplatelet drug in ischemic heart disease in noncardiac surgery

Abstract

The article raises the question of antiplatelet therapy in patients with ischemic heart disease in the perioperative period in non-cardiac surgical interventions. The article defines the indications for taking one or two antiplatelet agents in coronary heart disease patients, depending on the ischemic risk and the risk of bleeding. At the same time, there is presented a gradation of operations according to the risk of significant blood loss and the possibility of performing interventions on taking one or two antiplatelet agents. The deadlines for the cancellation of certain antiplatelet drugs before the surgery have been determined. Based on the studied literature and guidelines, the issue of safety and expediency of maintaining antiplatelet therapy in the perioperative period in various groups of patients with ischemic heart disease, depending on their somatic status, is discussed. An algorithm for choosing the optimal medical tactics is provided.

Keywords:antiplatelet agent, thrombus, surgery, risk, stenting, complication

Funding. The article was not sponsored.
Conflict of interests. The authors declare no conflict of interests.
Contribution. Definition of the scientific concept, collection and analysis of literature - Chomakhidze P.Sh.; participation in the collection and analysis of literature, in writing the text of the article - Bykova A.A., Novikov A.I.; scientific work management, making the necessary corrections, the final edition of the article - Andreev D.A.
For citation: Chomakhidze P.Sh., Bykova A.A., Novikova A.I., Andreev D.A. Antiplatelet drug in ischemic heart disease in noncardiac surgery. Clinical and Experimental Surgery. Petrovsky Journal. 2020; 8 (4): 43-8. DOI: https://doi.org/10.33029/2308-1198-2020-8-4-43-48 (in Russian)

References

1. Windecker S., Kolh P., Alfonso F., et al. 2014 ESC/ EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J. 2014; 35: 2541619. DOI: https://doi.org/10.1093/eurheartj/ehu278

2. Kozek-Langenecker S.A., Ahmed A.B., Afshari A., et al. Management of severe perioperative bleeding. Eur J Anaesthesiol. 2017; 34 (6): 332-95. DOI: https://doi.org/10.1097/EJA.0000000000000630

3. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 1329-39.

4. Knuuti J., Wijns W., Saraste A., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology. Eur Heart J. 2020; 41 (3): 407-77. DOI: https://doi.org/10.1093/eurheartj/ehz425

5. Kristensen S.D., Knuuti J., Saraste A., Anker S., Botker H.E., et al. ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 2014; 35: 2383-431. DOI: https://doi.org/10.1093/eurheartj/ehu282

6. Antithrombotic Tria lists’ (ATT) Collaboration; Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849-60.

7. Mauri L., Kereiakes D.J., Yeh R.W., Driscoll-Shempp P., Cutlip D.E., Steg P.G., et al.; DAPT Study Investigators. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014; 371: 2155-66.

8. Bonaca M.P., Bhatt D.L., Cohen M., Steg P.G., Storey R.F., Jensen E.C., et al.; PEGASUS-TIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791-800.

9. Eikelboom J.W., Connolly S.J., Bosch J., Dage-nais G.R., Hart R.G., et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017; 377: 1319-30.

10. Costa F., Van Klaveren D., Feres F., James S., et al. Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting. J Am Coll Cardiol. 2019; 73 (7): 741-54.

11. Egholm G., Kristensen S.D., Thim S.T., Ole-sen K.K.W., et al. Risk associated with surgery within 12 months after coronary drug-eluting stent implantation // J. Am. Coll. Cardiol. 2016. Vol. 68, N 24. P. 2633-2636. DOI: https://doi.org/10.1016/jjacc.2016.09.967

12. Valgimigli M., Bueno H., Byrne R.A., Collet J.-P., Costa F., Jeppsson A., et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery. J Cardiol. 2018; 23 (8): 113-63. DOI: http://doi.org/10.15829/1560-4071-2018-8-113-163

13. Palmerini T., Benedetto U., Bacchi-Reggiani L., Della Riva D., Biondi-Zoccai G., et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015; 385: 2371-82.

14. Navarese E.P., Andreotti F., Schulze V., Kolodziejc-zak M., Buffon A., Brouwer M., et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015; 350: h1618.

15. Giustino G., Baber U., Sartori S., Mehran R., Mastoris I., Kini A.S., et al. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2015; 65: 1298-310.

16. Gwon H.C., Hahn J.Y., Park K.W., Song Y.B., Chae I.H., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012; 125: 505-13.

17. Valgimigli M., Campo G., Monti M., Vranckx P., Percoco G., et al. Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012; 125: 2015-26.

18. Kim B.K., Hong M.K., Shin D.H., Nam C.M., Kim J.S., et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012; 60: 1340-8.

19. Feres F., Costa R.A., Abizaid A., Leon M.B., Marin-Neto J.A., et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013; 310: 2510-22.

20. Ellis S.G., Kereiakes D.J., Metzger D.C., Caputo R.P., Rizik D.G., Teirstein P.S., et al.; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015; 373: 1905-15.

21. Urban P., Meredith I.T., Abizaid A., Pocock S.J., Carrie D., Naber C., et al.; LEADERS FREE Investigators. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015; 373: 2038-47.

22. Valgimigli M., Patialiakas A.,Thury A., McFadden E., Colangelo S., Campo G., et al.; ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015; 65: 805-15.

23. Kwak Y.L., Kim J.C., Choi Y.S., Yoo K.J., Song Y., Shim J.K. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after off-pump coronary artery bypass graft surgery. J Am Coll Cardiol. 2010; 56: 19942002.

24. Ranucci M., Baryshnikova E., Soro G., Ballotta A., De Benedetti D., Conti D. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg. 2011; 91: 123-9.

25. Ranucci M., Colella D., Baryshnikova E., Di Ded-da U. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth. 2014; 113: 970-6.

26. Patel A.Y., Eagle K.A., Vaishnava P., et al. Cardiac risk of noncardiac surgery. J Am Coll Cardiol. 2015; 66 (19): 2140-8. DOI: https://doi.org/10.1016/jjacc.2015.09.026

27. Gielen C., Dekkers O., Stijnen T., et al. The effects of pre and postoperative fibrinogen levels on blood loss after cardiac surgery: a systematic review and meta-analysis. Interact Cardiovasc Thorac Surg. 2014; 18: 292-8.

28. Erdoes G., Gerster G., Colucci G., et al. Prediction of postweaning fibrinogen status during cardiopulmonary bypass: an observational study in 110 patients. PLoS One. 2015; 10: e0126692.

29. Cywinski J.B., Alster J.M., Miller C., et al. Prediction of intraoperative transfusion requirements during orthotopic liver transplantation and the influence on postoperative patient survival. Anesth Analg. 2014; 118: 428-37.

30. Columbo J.A., Lambour A.J., Sundling R.A., Chau-han N.B., Bessen S.Y., et al. Meta-analysis of the impact of aspirin, clopidogrel, and dual antiplatelet therapy on bleeding complications in noncardiac surgery. Ann Surg. 2018; 267 (1): 1-10. DOI: https://doi.org/10.1097/SLA.0000000000002279

31. Devereaux P.J., Mrkobrada M., Sessler D.I., Leslie K., Alonso-Coello P., et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med. 2014; 370: 1494503. DOI: https://doi.org/10.1056/NEJMoa1401105

32. Burger W., Chemnitius J.M., Kneissl G.D., Rucker G. Low-dose aspirin for secondary cardiovascular prevention: cardiovascular risks after its peri-operative withdrawal vs. bleeding risks with its continuation: review and meta-analysis. J Intern Med. 2005; 257: 399-414.